These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 27841794)

  • 1. Plasma Level of Soluble Urokinase-type Plasminogen Activator Receptor Predicts the Severity of Acute Alcohol Pancreatitis.
    Nikkola A; Aittoniemi J; Huttunen R; Rajala L; Nordback I; Sand J; Laukkarinen J
    Pancreas; 2017 Jan; 46(1):77-82. PubMed ID: 27841794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma level of soluble urokinase plasminogen activator receptor (suPAR) predicts long-term mortality after first acute alcohol-induced pancreatitis.
    Aronen A; Aittoniemi J; Huttunen R; Nikkola A; Nikkola J; Limnell O; Nordback I; Sand J; Laukkarinen J
    Eur J Intern Med; 2019 Jun; 64():72-75. PubMed ID: 31060962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble urokinase plasminogen activator receptor associates with higher risk, advanced disease severity as well as inflammation, and might serve as a prognostic biomarker of severe acute pancreatitis.
    Zhang Q; Li L; Chen H; Zhang G; Zhu S; Kong R; Chen H; Wang G; Sun B
    J Clin Lab Anal; 2020 Mar; 34(3):e23097. PubMed ID: 31774228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma suPAR as a prognostic biological marker for ICU mortality in ARDS patients.
    Geboers DG; de Beer FM; Tuip-de Boer AM; van der Poll T; Horn J; Cremer OL; Bonten MJ; Ong DS; Schultz MJ; Bos LD
    Intensive Care Med; 2015 Jul; 41(7):1281-90. PubMed ID: 26100127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble urokinase-type plasminogen activator receptor (suPAR) in patients with acute pancreatitis (AP) - Progress in prediction of AP severity.
    Lipinski M; Rydzewska-Rosolowska A; Rydzewski A; Cicha M; Rydzewska G
    Pancreatology; 2017; 17(1):24-29. PubMed ID: 27914940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma soluble urokinase-type plasminogen activator receptor (P-suPAR) in the diagnostics between malignant and non-malignant pancreatic lesions.
    Aronen A; Aittoniemi J; Huttunen R; Nikkola A; Nikkola J; Limnell O; Sand J; Laukkarinen J
    Pancreatology; 2023 Mar; 23(2):213-217. PubMed ID: 36596714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
    Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
    Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble urokinase plasminogen activator receptor predicts mortality in patients with systemic inflammatory response syndrome.
    Raggam RB; Wagner J; Prüller F; Grisold A; Leitner E; Zollner-Schwetz I; Valentin T; Krause R; Hoenigl M
    J Intern Med; 2014 Dec; 276(6):651-8. PubMed ID: 24645798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble urokinase-type plasminogen activator receptor in patients with suspected infection in the emergency room: a prospective cohort study.
    Uusitalo-Seppälä R; Huttunen R; Tarkka M; Aittoniemi J; Koskinen P; Leino A; Vahlberg T; Rintala EM
    J Intern Med; 2012 Sep; 272(3):247-56. PubMed ID: 22755554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive value of soluble urokinase plasminogen activator receptor (SuPAR) regarding 90-day mortality and 12-month neurological outcome in critically ill patients after out-of-hospital cardiac arrest. Data from the prospective FINNRESUSCI study.
    Jalkanen V; Vaahersalo J; Pettilä V; Kurola J; Varpula T; Tiainen M; Huhtala H; Alaspää A; Hovilehto S; Kiviniemi O; Kuitunen A; Tenhunen J;
    Resuscitation; 2014 Nov; 85(11):1562-7. PubMed ID: 25193800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia.
    Erkut N; Menteşe A; Özbaş HM; Ermantaş N; Sümer A; Örem A; Sönmez M
    Turk J Haematol; 2016 Jun; 33(2):135-40. PubMed ID: 26376588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma suPAR may help to distinguish between chronic pancreatitis and pancreatic cancer.
    Aronen A; Aittoniemi J; Huttunen R; Nikkola A; Rinta-Kiikka I; Nikkola J; Limnell O; Nordback I; Sand J; Laukkarinen J
    Scand J Gastroenterol; 2021 Jan; 56(1):81-85. PubMed ID: 33245246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study.
    Rasmussen LJ; Ladelund S; Haupt TH; Ellekilde G; Poulsen JH; Iversen K; Eugen-Olsen J; Andersen O
    Emerg Med J; 2016 Nov; 33(11):769-775. PubMed ID: 27590986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic accuracy of soluble urokinase plasminogen activator receptor (suPAR) for prediction of bacteremia in patients with systemic inflammatory response syndrome.
    Hoenigl M; Raggam RB; Wagner J; Valentin T; Leitner E; Seeber K; Zollner-Schwetz I; Krammer W; Prüller F; Grisold AJ; Krause R
    Clin Biochem; 2013 Feb; 46(3):225-9. PubMed ID: 23159293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis.
    Savva A; Raftogiannis M; Baziaka F; Routsi C; Antonopoulou A; Koutoukas P; Tsaganos T; Kotanidou A; Apostolidou E; Giamarellos-Bourboulis EJ; Dimopoulos G
    J Infect; 2011 Nov; 63(5):344-50. PubMed ID: 21839112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.
    Koch A; Voigt S; Kruschinski C; Sanson E; Dückers H; Horn A; Yagmur E; Zimmermann H; Trautwein C; Tacke F
    Crit Care; 2011; 15(1):R63. PubMed ID: 21324198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of soluble urokinase plasminogen activator receptor in patients presenting to the emergency department with chest pain suggestive of acute coronary syndrome.
    Chenevier-Gobeaux C; Lemarechal H; Doumenc B; Peschanski N; Claessens YE; Borderie D; Ray P
    Clin Biochem; 2021 Jun; 92():19-24. PubMed ID: 33662350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble urokinase-type plasminogen activator levels are related to plasma cytokine levels but have low predictive value for mortality in trauma patients.
    Timmermans K; Vaneker M; Scheffer GJ; Maassen P; Janssen S; Kox M; Pickkers P
    J Crit Care; 2015 Jun; 30(3):476-80. PubMed ID: 25721031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble urokinase-type plasminogen activator receptor levels in patients with burn injuries and inhalation trauma requiring mechanical ventilation: an observational cohort study.
    Backes Y; van der Sluijs KF; Tuip de Boer AM; Hofstra JJ; Vlaar AP; Determann RM; Knape P; Mackie DP; Schultz MJ
    Crit Care; 2011; 15(6):R270. PubMed ID: 22085408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality.
    Zimmermann HW; Reuken PA; Koch A; Bartneck M; Adams DH; Trautwein C; Stallmach A; Tacke F; Bruns T
    J Intern Med; 2013 Jul; 274(1):86-100. PubMed ID: 23432143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.